Many Research Antibodies Fail in ALS Studies
Scientists and patients following ALS and Parkinson's research should know many commercial tools may not perform as advertised.
Updated on Nov. 4, 2026 in Alzheimer’s

Live Poll
Do you trust that most medical research findings are built on reliable lab tools?
A Montreal research team found that nearly two-thirds of commercial antibodies claimed to detect C9orf72, a protein linked to ALS, failed to do so. The study matters most for scientists and patients who depend on laboratory tools to study neurological disease.
Why it matters
Research antibodies are a foundational tool in disease studies, so unreliable reagents can produce inaccurate conclusions and dubious studies that slow progress on treatments. The team's work suggests the problem may extend well beyond ALS, since around 100 proteins have been linked to Parkinson's disease.
The Montreal team tested commercial antibodies against the gold-standard reference for C9orf72, a protein tied to ALS, and found that nearly two-thirds of those marketed as detecting it did not. The team has since launched a free public database of its results, though its full scope across all antibody targets is not yet clear.
The players
Neuro (Montreal Neurological Institute-Hospital)
A research institute affiliated with McGill University that studies neurological diseases, including ALS and Parkinson's disease.
Carl Laflamme
A researcher at the University of Ottawa who led the antibody study on C9orf72 and ALS-linked proteins.
The details
Antibodies are protein tools that bind to a specific target so researchers can see and measure it in cells and tissue. The Neuro team compared commercial antibodies against a verified gold standard to confirm whether each one actually recognized C9orf72. Because a failed antibody can still produce a signal, a study can appear to show a result that is not really there, which is why verification against a reference matters.
Timeline
Findings on unreliable research antibodies were published on November 4, 2026, in the journal eLife.
Health Landscape
The reliability of research antibodies has become a growing concern in neurodegenerative disease research, where many studies depend on a small set of reagents. This Montreal effort, through its public ALS-Reproducible Antibody Platform, offers a shared way to check tools before they shape the conclusions of studies on ALS and Parkinson's disease.
If you or a family member is following research on ALS or Parkinson's disease, it is reasonable to recognize that study results depend on the quality of lab tools and that new findings may take time to be confirmed. Questions about how a neurological condition is diagnosed or monitored are worth raising with your doctor or a neurologist.
The takeaway
Research findings are only as reliable as the tools used to produce them, so it is worth treating early disease-biology claims with appropriate caution. Patients and families can ask their clinicians which research is well established before making decisions based on a single study.
Further reading
For background on how disease research tools are validated, explore our Alzheimer’s coverage.
Source note: This article includes information reported by CityNews Montreal.
Live Poll
Do you trust that most medical research findings are built on reliable lab tools?


